pocketful logo light
pocketful logo light
Lupin Ltd logo

Lupin Ltd

NSE: LUPIN BSE: 500257

2415

(0.26%)

Mon, 03 Aug 2026, 04:07 pm

Lupin Share Price Live Chart

1 Day

(0.26%)

No Result Found

Summary

  • Market Cap (in Cr)

    103900.02

  • Net Profit (in Cr)

    3306.26

  • P/B

    5.38

  • Sector P/E

    33.76

  • P/E

    28.20

  • EV/EBITDA

    17.31

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    21

  • ROCE

    20.88

  • Debt/Equity

    0.27

  • EPS (TTM)

    126.13

  • Dividend Yield

    0.79

  • Book Value

    490.98

  • Interest Cover

    14.62

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends after 3 years are expected to be well covered by earnings (6.1x coverage).
  • Lupin's earnings are expected to grow significantly at over 20% yearly.
  • Lupin's earnings growth is expected to exceed the India market average.
  • Lupin's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • The company is paying a dividend however it is incurring a loss.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Lupin's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Lupin's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Lupin is expected to increase but not above the 50% threshold in 2 years time.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters46.8646.8946.9046.9046.92
FII21.7121.4920.4921.2521.46
DII25.3225.5826.5525.5625.41
Public6.116.036.066.286.20
Government0.000.010.010.010.01

Read More

Technical Analysis

RSI

46.72

MACD

4.45

50 DMA

2370.06

200 DMA

2222.56

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2807.172617.672516.332428.172326.832238.672049.17
Fibonacci2617.672545.282500.562428.172355.782311.062238.67
Camarilla2467.112449.742432.372428.172397.632380.262362.89

Pivots Level: Classic

R3

+379

2807.17

R2

+189.50

2617.67

R1

+88.17

2516.33

2428.17
2428.17
Pivot Point
LTP: 2393

S1

-101.33

2326.83

S2

-189.50

2238.67

S3

-379

2049.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2419.83

  • 20-EMA

    2423.21

  • 30-EMA

    2413.39

  • 50-EMA

    2389.37

  • 100-EMA

    2336.17

  • 200-EMA

    2250.78

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
07 May 2026board-meetingsAccounts, Quarterly Results, Dividend
12 Feb 2026board-meetingsQuarterly Results
06 Nov 2025board-meetingsQuarterly Results
14 Jul 2025agm
25 Jun 2025dividendFinal Dividend - Rs. - 1225 Jul 2025
14 May 2025dividend₹12.00 Dividend /Share25 Jul 2025
09 Jul 2024agm
16 Jun 2024dividendFinal Dividend - Rs. - 816 Jul 2024
06 May 2024dividend₹8.00 Dividend /Share16 Jul 2024
04 Jul 2023agm

Read More

Peer Comparison

Lupin Ltd logo

Lupin Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Lupin Ltd About

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, Gastro- Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. The Company along with its subsidiaries has manufacturing locations spread across India, USA, Mexico and Brazil with trading and other incidental and related activities extending to the global markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1983

Headquarters

CEO

M D Gupta

Employees

Contact

Website icon

Website

https://www.lupin.com/

Email icon

Email

investorservices@lupinpharma.com

Phone icon

Phone

91-22-6640 2323

Location icon

Location

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Read More

Lupin Ltd Company History

YearHistory
2020
  • Lupin's Pithampur facilities pass MHRA inspection.
  • Lupin launches generic arthritis relief tablet in the US.
  • Lupin receives EIR from US FDA for Florida inhalation research centre.
  • Lupin receives EIR from US FDA for Nagpur plant.
  • Lupin receives US FDA approval for generic product.
2021
  • Lupin receives US FDA approval for generic anti-fungal cream.
  • LupinLife launches ayurvedic energy supplement Be One.
  • Lupin launches Posaconazole delayed-release tablets.
  • Lupin launches generic Wilson's disease drug in the US.
  • Lupin launches generic diarrhea drug in the US.
2022
  • Lupin receives US FDA approval for Efinaconazole Topical Solution.
  • Lupin launches first reference laboratory in Kolkata.
  • Lupin receives US FDA approval for Vigabatrin for Oral Solution USP.
  • Lupin completes acquisition of brands from Anglo-French.
  • Lupin launches Merzee Capsules in the US.
2023
  • Lupin launches Softovac Liqui fibre liquid fibre product.
  • Lupin launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the US.
  • Lupin launches Rocuronium Bromide Injection in the US.
  • Lupin launches Diazepam Rectal Gel in the US.
  • Lupin agrees to acquire 5 drug brands from Menarini for Rs 101 crore.
2024
  • Lupin and Slurrp conclude Lupin Aptivate Achchi Bhookh Quiz.
  • Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio.
  • Lupin receives US FDA approval for Emtricitabine and Tenofovir Alafenamide Tablets.
  • Lupin acquires 3 trademarks from Boehringer Ingelheim to strengthen diabetes portfolio.
  • Lupin's Pune R&D facility awarded LEED Platinum Certification.
  • Lupin launches Bumetanide Injection USP in the United States.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell600351937.514 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy600351937.514 Oct 2025
GOLDMAN SACHS BANK EUROPE SE - ODIblockBuy81892197713 Oct 2025
GOLDMAN SACHS (SINGAPORE) PTE - ODIblockSell81892197713 Oct 2025
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDblockSell528611894.714 Jul 2025
STATE STREET MSCI ACWI EX USA IMI SCREENED NON-LENDING COMMON TRUST FUNDblockBuy528611894.714 Jul 2025
BNP PARIBAS ARBITRAGEblockSell7479561449.225 Jan 2024
SOCIETE GENERALEblockBuy7479561449.225 Jan 2024
ISHARES CORE EMERGING MARKETS MAURITIUS COblockSell22847774714 Nov 2022
ISHARES CORE MSCI EMERGING MARKETS ETFblockBuy22847774714 Nov 2022

Read More

Lupin Ltd News

Lupin Receives U.S. Approval for Diazepam Injection

Lupin has received approval for Diazepam Injection in the U.S. market, marking a regulatory milestone for the pharmaceutical company.

28 Jul 2026

companies

Lupin to host Q1 FY27 earnings call

Lupin Limited will hold an earnings call for Q1 FY27 on August 7, 2026, at 16:30 IST to discuss financial results.

22 Jul 2026

companies

Lupin subsidiary acquires 82.2% stake in Kaveri Therapeutics

Lupin Inc. acquired an 82.2% equity stake in Kaveri Therapeutics for an exclusive license to two oncology programs valued at USD 1.6 million.

21 Jul 2026

companies

Lupin Block Trade: Rs. 27.12 Cr for ~1,10,946 Shares

A block trade worth Rs. 27.12 crores was executed on the NSE for approximately 1,10,946 shares of Lupin Ltd. at a price of Rs. 2444.40 per share.

17 Jul 2026

equity-markets

Lupin Sees ₹99.88 Cr Block Trade on BSE

A block trade worth ₹99.88 crore was executed on BSE for approximately 400000 shares of Lupin at ₹2497 per share.

15 Jul 2026

equity-markets

Read More

Frequently Asked Questions

  • 1.What is the stock price of Lupin Ltd?

    As of 03/08/2026 at 9:37 PM, Lupin Ltd shares are trading at 2415.

  • 2.What is the market cap. of Lupin Ltd?

    As of 03/08/2026, the market capitalization of Lupin Ltd is 1,10,374.21 crore.

  • 3.When was Lupin Ltd founded?

    Lupin Ltd was founded in 1983.

  • 4.What are the P/E and P/B ratios of Lupin Ltd?

    As of 03/08/2026, Lupin Ltd has a P/E ratio of 20.74 and a P/B ratio of 5.38.

  • 5.How can I buy shares of Lupin Ltd?

    You can buy shares of Lupin Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Lupin Ltd?

    As of March,2026, promoters hold 46.86% in Lupin Ltd, while FIIs, DIIs and public shareholders hold 21.71%, 25.32% and 6.11%, respectively. The government holds 0.00%.

  • 7.Does Lupin Ltd pay dividends?

    Yes, Lupin Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was Final Dividend - Rs. - 12 per share.

  • 8.What is the dividend yield of Lupin Ltd?

    As of 03 August, 2026, the dividend yield of Lupin Ltd stands at 0.75%.

  • 9.What are the latest financial results of Lupin Ltd?

    For January,2024, Lupin Ltd reported revenue of 22,228.00 crore and a net profit of 3,282.00 crore.

  • 10.What is the Stock symbol of Lupin Ltd?

    LUPIN is the stock symbol of Lupin Ltd.

  • 11.Who is the CEO of Lupin Ltd?

    The CEO of Lupin Ltd is M D Gupta.

Open Your Free Demat Account

Enter your phone number